Conflict of interest: C. Brightling reports grant and fees for consultancy (paid to institution) from GlaxoSmithKline, AstraZeneca/Medimmune, Novartis, Boehringer Ingelheim, Chiesi and Roche/Genentech, personal fees for consultancy (paid to institution) from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron, Teva, Gossamer and 4DPharma, and institutional grants from Pfizer and Mologic, outside the submitted work. Conflict of interest: C. Genton reports multi-sponsored study fees from Chiesi, Sanofi, Grifols, Novartis, Insmed, Zambon, TEVA and GlaxoSmithKline, outside the submitted work. C. Genton is an employee of the ERS. Conflict of interest: W. Bill is executive director of the ERS. Conflict of interest: T. Welte reports institutional grants from AstraZeneca, Bayer, Grifols, Insmed, Novartis, Pfizer and Boehringer, and personal fees for advisory board work and lectures from AstraZeneca, Bayer, Boehringer, GSK, Grifols, Insmed, Novartis, Sanofi and Pfizer, outside the submitted work. Conflict of interest: M. Gaga has nothing to disclose. Conflict of interest: E. Heuvelin reports multi-sponsored study fees from Chiesi, Sanofi, Grifols, Novartis, Insmed, Zambon, TEVA and GlaxoSmithKline, outside the submitted work. E. Heuvelin is an employee of the ERS. Conflict of interest: G. Brusselle reports personal fees for advisory board work and speaking from AstraZeneca, Boehringer-Ingelheim, Chiesi, Novartis, GlaxoSmithKline and Teva, and personal fees for advisory board work from Sanofi, outside the submitted work.